Paper9819829
Optimal flexible designs in phase II clinical trials.
Chen TT and 1 other. Stat Med, 1998. Cited by 100 papers, by iCite.
Cite this record
ConductScience Library. Optimal flexible designs in phase II clinical trials. Papers, record 9819829. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9819829
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics3
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Clinical Trials, Phase II as Topic | Major topic |
| Research Design | |
| Statistics as Topic |
Source PubMed
Cited by54
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 100 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 38603953 | Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016. | Gynecol Oncol | 2024 | https://conductscience.org/library/papers/38603953 | PubMed |
| 38574312 | Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279. | J Clin Oncol | 2024 | https://conductscience.org/library/papers/38574312 | PubMed |
| 38473419 | The Potential Influence of Residual or Recurrent Disease on Bevacizumab Treatment Efficacy in Ovarian Cancer: Current Evidence and Future Perspectives. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38473419 | PubMed |
| 37418832 | A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283. | Gynecol Oncol | 2023 | https://conductscience.org/library/papers/37418832 | PubMed |
| 35868503 | Inefficiency of two-stage designs in phase II oncology clinical trials with high proportion of inevaluable patients. | Contemp Clin Trials | 2022 | https://conductscience.org/library/papers/35868503 | PubMed |
| 34875107 | A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability. | Cancer | 2022 | https://conductscience.org/library/papers/34875107 | PubMed |
| 33717225 | Profiling of circulating tumor DNA and tumor tissue for treatment selection in patients with advanced and refractory carcinoma: a prospective, two-stage phase II Individualized Cancer Treatment trial. | Ther Adv Med Oncol | 2021 | https://conductscience.org/library/papers/33717225 | PubMed |
| 31934607 | Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008). | Gynecol Oncol Rep | 2020 | https://conductscience.org/library/papers/31934607 | PubMed |
| 31924334 | Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). | Gynecol Oncol | 2020 | https://conductscience.org/library/papers/31924334 | PubMed |
| 30309721 | A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study. | Gynecol Oncol | 2018 | https://conductscience.org/library/papers/30309721 | PubMed |
| 28774461 | Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. | Gynecol Oncol | 2017 | https://conductscience.org/library/papers/28774461 | PubMed |
| 28303530 | A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3-1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer. | Invest New Drugs | 2017 | https://conductscience.org/library/papers/28303530 | PubMed |
| 28029447 | A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study. | Gynecol Oncol | 2017 | https://conductscience.org/library/papers/28029447 | PubMed |
| 27500329 | Second Curettage for Low-Risk Nonmetastatic Gestational Trophoblastic Neoplasia. | Obstet Gynecol | 2016 | https://conductscience.org/library/papers/27500329 | PubMed |
| 26975418 | A Phase II Efficacy and Safety, Open-Label, Multicenter Study of Imprime PGG Injection in Combination With Cetuximab in Patients With Stage IV KRAS-Mutant Colorectal Cancer. | Clin Colorectal Cancer | 2016 | https://conductscience.org/library/papers/26975418 | PubMed |
| 26616224 | A phase II study of paclitaxel for the treatment of ovarian stromal tumors: An NRG Oncology/ Gynecologic Oncology Group Study. | Gynecol Oncol | 2016 | https://conductscience.org/library/papers/26616224 | PubMed |
| 26368810 | A Rescue Strategy for Handling Unevaluable Patients in Simon's Two Stage Design. | PLoS One | 2015 | https://conductscience.org/library/papers/26368810 | PubMed |
| 26368744 | Nine-year change in statistical design, profile, and success rates of Phase II oncology trials. | J Biopharm Stat | 2016 | https://conductscience.org/library/papers/26368744 | PubMed |
| 26048655 | Statistical inference for extended or shortened phase II studies based on Simon's two-stage designs. | BMC Med Res Methodol | 2015 | https://conductscience.org/library/papers/26048655 | PubMed |
| 25818403 | A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. | Gynecol Oncol | 2015 | https://conductscience.org/library/papers/25818403 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/9819829
GET https://conductscience.org/api/papers/v1/9819829/cited_by?page=2